JP2024520853A5 - - Google Patents

Info

Publication number
JP2024520853A5
JP2024520853A5 JP2023576218A JP2023576218A JP2024520853A5 JP 2024520853 A5 JP2024520853 A5 JP 2024520853A5 JP 2023576218 A JP2023576218 A JP 2023576218A JP 2023576218 A JP2023576218 A JP 2023576218A JP 2024520853 A5 JP2024520853 A5 JP 2024520853A5
Authority
JP
Japan
Prior art keywords
conjugated antibody
cancer
antibody according
amino acids
conjugated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520853A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032545 external-priority patent/WO2022261124A1/en
Publication of JP2024520853A publication Critical patent/JP2024520853A/ja
Publication of JP2024520853A5 publication Critical patent/JP2024520853A5/ja
Pending legal-status Critical Current

Links

JP2023576218A 2021-06-11 2022-06-07 Ｎ－ホルミル－ハロゲン化メチオニン残基を含むペプチドおよびその操作された抗体－ペプチドコンジュゲート Pending JP2024520853A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163209762P 2021-06-11 2021-06-11
US63/209,762 2021-06-11
US202163210292P 2021-06-14 2021-06-14
US63/210,292 2021-06-14
PCT/US2022/032545 WO2022261124A1 (en) 2021-06-11 2022-06-07 Peptides comprising n-formyl-halogenated methionine residues and engineered antibody-peptide conjugates thereof

Publications (2)

Publication Number Publication Date
JP2024520853A JP2024520853A (ja) 2024-05-24
JP2024520853A5 true JP2024520853A5 (https=) 2025-06-16

Family

ID=82482577

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023576218A Pending JP2024520853A (ja) 2021-06-11 2022-06-07 Ｎ－ホルミル－ハロゲン化メチオニン残基を含むペプチドおよびその操作された抗体－ペプチドコンジュゲート

Country Status (4)

Country Link
US (1) US20240285787A1 (https=)
EP (1) EP4351656A1 (https=)
JP (1) JP2024520853A (https=)
WO (1) WO2022261124A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609083D0 (en) * 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
CN116143832A (zh) * 2023-04-17 2023-05-23 中国中医科学院医学实验中心 一种甲拌磷半抗原及其合成工艺

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200155702A1 (en) 2017-06-16 2020-05-21 Eli Lilly And Company Engineered Antibody Compounds and Conjuates Thereof

Similar Documents

Publication Publication Date Title
DK2694111T3 (en) Antibody pharmaceutical conjugates
JP6529478B2 (ja) １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）
JP2022106976A (ja) 操作された抗体化合物およびこれらの抱合体
CN108101825B (zh) 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途
JP2024075771A (ja) 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用
TW201116300A (en) DR5 Ligand Drug Conjugates
CN107530422A (zh) Cd48抗体和其缀合物
RU2737553C2 (ru) Материалы и способы, связанные с линкерами для применения в конъюгатах лекарственного средства и белка
JP2024520853A5 (https=)
CN110352074A (zh) 用于偶联的半胱氨酸突变抗体
JP2025533983A (ja) リンカー－ペイロード化合物、複合体、及びその用途
Barginear et al. Trastuzumab-DM1: a review of the novel immuno-conjugate for HER2-overexpressing breast cancer
US20240285787A1 (en) Peptides comprising n-formyl-halogenated methionine residues and engineered antibody-peptide conjugates thereof
CN117750981A (zh) 包含n-甲酰基-卤代甲硫氨酸残基的肽及其工程化抗体-肽缀合物
CN121941709A (zh) 抗cdh17抗体-药物偶联物及其制备和使用方法
HK40044344A (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
HK40011245A (en) Cysteine mutated antibodies for conjugation